检索结果-南通市图书馆

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci xiao-Jun Bi yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai wujun Cai Yijian Cai Yizhou Cai yuchen Cai haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che yuzhi Che bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen Wei Chen xiang Chen xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen Ying Chen yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

基于二维相关荧光谱土壤中PAHs检测方法研究

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

光谱学与光谱分析 2019年第3期39卷 818-822页

作者：杨仁杰王斌董桂梅杨延荣吴楠孙国红张伟玉刘海学天津农学院工程技术学院天津300384 南开大学物理学院光子学中心天津300071 天津农学院农业分析测试中心天津300384

传统荧光光谱技术已被用于土壤中多环芳烃(PAHs)的检测,但由于土壤体系的复杂性、 PAHs污染物的多样化和微量化,传统的荧光光谱技术无法有效提取土壤中PAHs的特征信息。为了解决上述问题,提出并建立一种基于二维相关荧光谱土壤中多环芳... 详细信息

传统荧光光谱技术已被用于土壤中多环芳烃(PAHs)的检测,但由于土壤体系的复杂性、 PAHs污染物的多样化和微量化,传统的荧光光谱技术无法有效提取土壤中PAHs的特征信息。为了解决上述问题,提出并建立一种基于二维相关荧光谱土壤中多环芳烃的检测方法。以土壤中典型的多环芳烃蒽和菲为研究对象,配置38个蒽菲混合标准土壤样品(蒽和菲的浓度范围均为0.000 5～0.01 g·g^(-1)),在激发波长265～340 nm,发射波长350～500 nm范围内采集了所有样品的三维荧光谱。以激发波长为外扰,对外扰变化的动态一维荧光谱进行相关计算,得到每一样品的同步二维相关荧光谱。研究了浓度均为0.005 g·g^(-1)蒽菲混合土壤样品的三维荧光谱和同步二维相关荧光谱特性,在同步谱主对角线398, 419, 444和484 nm处存在自相关峰,其中, 398和484 nm荧光峰来自土壤中的菲, 419和444 nm荧光峰来自土壤中的蒽;在主对角线外侧,蒽和菲两组荧光峰之间存在负的交叉峰,进一步验证了其来源不同;同时,在(408, 434) nm和(434, 467) nm处出现交叉峰,其中408和434 nm荧光峰来自土壤中的菲, 467 nm荧光峰来自土壤中的蒽。指出与三维荧光谱表征的信息相比,二维相关荧光谱不仅能提取更多的特征信息(408和467 nm的特征峰在三维荧光谱中未被表征),而且还能提供荧光峰之间的相互关系,对其来源进行有效解析。在上述研究二维相关荧光谱特性的基础上,基于同步相关谱矩阵(38×151×151)建立了定量分析土壤中蒽和菲污染物浓度的多维偏最小二乘(N-PLS)模型,对蒽的校正和预测相关系数分别为0.986和0.985,校正均方根误差(RMSEC)和预测均方根误差(RMSEP)分别为4.33×10^(-4)和5.55×10^(-4) g·g^(-1);对菲的校正和预测相关系数分别为0.981和0.984, RMSEC和RMSEP分别为5.20×10^(-4)和4.80×10^(-4) g·g^(-1)。为了比较,基于三维荧光光谱矩阵(38×16×151)建立了定量了分析土壤中蒽和菲的N-PLS模型,对蒽的校正和预测相关系数分别为0.981和0.972, RMSEC和RMSEP分别为5.09×10^(-4)和6.74×10^(-4) g·g^(-1);对菲的校正和预测相关系数分别为0.957和0.956, RMSEC和RMSEP分别为7.36×10^(-4)和7.77×10^(-4) g·g^(-1)。指出,对于土壤中的蒽和菲检测,基于二维相关荧光谱的N-PLS模型的相关系数r, RMSEC和RMSEP都要优于基于三维荧光谱的N-PLS模型。研究结果表明:所提出和建立的方法—二维相关荧光谱直接检测土壤中PAHs污染物不仅可行,而且能提供更好的分析结果。该研究为激光诱导荧光结合相关谱技术现场直接检测土壤中多环芳烃污染物提供了理论和实验基础,具有较好的应用前景。

关键词：土壤多环芳烃二维相关荧光谱蒽菲

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： ren-Yi Su sun-bin Ling Qiao-Nan Shan Xu-Yong Wei Rui Wang Chang-Ku Jia Li Zhuang Tian Shen Li-Min Ding Zhi-Dan Xu Lai-Bang Luo Li-Bo sun Guang-Ming Li Tai-Shi Fang Nan Jiang Kun Zhang Zhao-jie Su Zhi-hai Peng ren Lang Tao Jiang Qiang He Lin-Sen Ye Yang Yang yu-Ting He Wen-Zhi Guo Liu-Gen Lan Xu-Yong sun Dong Chen Zhi-Shui Chen Da-Wei Zhou Shao-Jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi Bo Wang Jiang Liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang Lin Zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong wu Chang-Jiang Lu Cai-De Lu Dong-Hua Zhang Xuan Wang Zi-Qiang Li Mu-Jian Teng Jun-jie Li Wen-Tao Jiang Jian-Hua Li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang xia Shao-Hua Song Zhi-ren Fu Wei Qiu Guo-yue Lv Rui-Peng Song Ji-Zhou Wang Zheng Wang Jian Zhou Gang Chen Ying-Peng Zhao Li Li Ze-Min Hu Qi-jie Luo Zhong-Zhou Si bin Xie xiao-Shun He Zhi-Yong Guo Shu-Sen Zheng xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2013年第12期126卷 2276-2280页

作者： ZHENG Ying CAI Guang-yan CHEN xiang-mei FU Ping CHEN Jiang-hua DING xiao-qiang yu Xue-qing LIN Hong-li LIU Jian XIE Ru-juan WANG Li-ning NI Zhao-hui LIU Fu-you YIN Ai-ping XING Chang-ying WANG Li SHI Wei LIU Jian-she HE Ya-ni DING Guo-hua LI Wen-ge wu Guang-li MIAO Li-ning CHEN Nan SU Zhen MEI Chang-lin ZHAO Jiu-yang GU Yong BAI yun-kai LUO Hui-min LIN Shan CHEN Meng-hua GONG Li YANG Yi-bin YANG xiao-ping LI Ying WAN Jian-xin WANG Nian-song LI hai-ying XI Chun-sheng HAO Li XU Yan FANG Jing-ai LIU Bi-cheng LI Rong-shan WANG Rong ZHANG Jing-hong WANG Jian-qin LOU Tan-qi SHAO Feng-min MEI Feng LIU Zhi-hong yuAN Wei-jie sun Shi-ren ZHANG Ling ZHOU Chun-hua CHEN Qin-kai JIA Shun-lian GONG Zhi-feng GUAN Guang-ju xia Tian ZHONG Liang-bao Department of Nephrology State key Laboratory of Kidney Disease Chinese PLA General Hospital Beijing 100853 China Nephrology Institute of the Chinese People's Liberation Army Chinese People's Liberation Army Key Laboratory of Nephrology Beijing 100853 China Department of Nephrology West China Hospital of Sichuan University Chengdu Sichuan 610041 China Department of Nephrology First Affiliated Hospital School of Medicine Zhejiang University Hangzhou Zhejiang 310003 China Department of Nephrology Zhongshan Hospital Fudan University Shanghai 200032 China Department of Nephrology First Affiiated Hospital of Sun Yat-sen University Guangzhou Guangdong 510080 China Department of Nephrology First Affiliated Hospital of Dalian Medical University Dalian Liaoning 116011 China Department of Nephrology First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang 830054 China Department of Nephrology First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150001 China Department of Nephrology First Afftiated Hospital of China Medical University Shenyang Liaoning 110001 China Department of Nephrology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai 200025 China Department of Nephrology Second Xiangya Hospital Central South University Changsha Hunan 410000 China Department of Nephrology First Affiliated Hospital of Medical College Xi'an Jiaotong University Xi'an Shaanxi 710061 China Department of Nephrology First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) Nanjing Jiangsu 210029 China Department of Nephrology Sichuan Provincial People's Hospital Chengdu Sichuan 610072 China Department of Nephrology Guangdong Provincial People's Hospital Guangzhou Guangdong 510030 China Department of Nephrology Affliated Xiehe Hospital Tongji Medical College Huazhong Science and Technology University Wuhan Hubei 430022 China Department of Nephrology Daping Hospital Third Military Medi

Background Data on the epidemiology of hypertension in Chinese non-dialysis chronic kidney disease （CKD） patients are *** aim of the present study was to investigate the prevalence,awareness,treatment,and control of hypertension in the non-dialysis CKD patients through a nationwide,multicenter study in *** The survey was performed in 61 tertiary hospitals in 31 provinces,municipalities,and autonomous regions in China （except Hong Kong,Macao,and Taiwan）.Trained physicians collected demographic and clinical data and measured blood pressure （BP） using a standardized *** was defned as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg,and/or use of antihypertensive *** 〈140/90 mmHg and 〈130/80 mmHg were used as the 2 thresholds of hypertension *** multivariate logistic regression with adjustment for sex and age,we analyzed the association between CKD stages and uncontrolled hypertension in non-dialysis CKD *** The analysis included 8927 non-dialysis CKD *** prevalence,awareness,and treatment of hypertension in non-dialysis CKD patients were 67.3%,85.8%,and 81.0%,*** hypertensive CKD patients,33.1% and 14.1% had controlled BP to 〈140/90 mmHg and 〈130/80 mmHg,*** successive CKD stages,the prevalence of hypertension in non-dialysis CKD patients increased,but the control of hypertension decreased （P〈0.001）.When the threshold of BP 〈130/80 mmHg was considered,the risk of uncontrolled hypertension in CKD 2,3a,3b,4,and 5 stages increased 1.3,1.4,1.4,2.5,and 4.0 times compared with CKD 1 stage,respectively （P〈0.05）.Using the threshold of 〈140/90 mmHg,the risk of uncontrolled hypertension increased in advanced stages （P〈0.05）.Conclusions The prevalence of hypertension Chinese non-dialysis CKD patients was high,and the hypertension control was *** successive CKD stages,the risk of uncontrolled hypertension increased.

关键词： non-dialysis chronic kidney disease chronic kidney disease stages hypertension epidemiology

新思路·新技术——中药复方新药研发相关重大科学和技术问题

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国药理学与毒理学杂志 2020年第4期34卷 241-260页

作者：蒋宁杜保民杜冠华段大跃方坚松高兴华高秀梅顾金辉郭彦飞侯悦黄晏李琦林志彬刘建勋陆茵吕圭源聂红庞晓斌齐晓甜秦雪梅任巧任远任周新茹祥斌申竹芳石京山孙建宁孙蓉孙晓波王陈王梅王同兴吴春福谢宗杰徐惠波薛云丽杨宝学杨奎余林中张丹参张兰张林张永鹤张永祥赵勤实周玉枝朱焰周文霞军事科学院军事医学研究院毒物药物研究所北京100850 北京北大维信生物科技有限公司北京100094 中国医学科学院北京协和医学院药物研究所北京100050 西南医科大学附属中医医院中医药表型组学中心四川泸州646000 广州中医药大学科技创新中心广东广州510006 中国药科大学江苏南京210009 天津中医药大学天津301617 国家卫生健康委员会科技教育司重大专项处北京100044 东北大学辽宁沈阳110819 中国中医科学院中药研究所北京100700 北京大学基础医学院北京100191 中国中医科学院西苑医院北京100091 南京中医药大学药学院江苏南京210023 浙江中医药大学现代中药与健康产品研究所浙江杭州310053 广东省药效物质基础和创新药物研究重点实验室广东广州510632 河南大学药学院河南开封475004 山东大学高等医学研究院山东济南250012 山西大学中医药现代研究中心山西太原030006 甘肃中医药大学甘肃兰州730000 河南中医药大学河南郑州450046 遵义医科大学贵州遵义563003 北京中医药大学北京100029 中国医学科学院药用植物研究所北京100193 莱顿大学-欧洲中医药和天然化合物中心荷兰莱顿天士力国际基因网络药物创新中心有限公司天津300410 沈阳药科大学辽宁沈阳110016 吉林省中医药科学院吉林长春130012 山东绿叶制药有限公司山东烟台264003 成都中医药大学四川成都611137 南方医科大学广东广州510515 河北科技大学河北石家庄050018 首都医科大学宣武医院北京100053 中国科学院昆明植物研究所云南昆明650201 复旦大学上海200433

"第十二届全国中药与天然药物药理学术会议"于2019年10月11-13日在天津市社会山国际会议中心酒店举行。会议期间,中国药理学会中药与天然药物药理专业委员会召开了"中药复方新药研发相关重大科学和技术问题"专题研讨会。研讨会分为主题... 详细信息

"第十二届全国中药与天然药物药理学术会议"于2019年10月11-13日在天津市社会山国际会议中心酒店举行。会议期间,中国药理学会中药与天然药物药理专业委员会召开了"中药复方新药研发相关重大科学和技术问题"专题研讨会。研讨会分为主题报告和综合讨论2部分。主题报告由中国药理学会中药与天然药物药理专业委员会副主任委员吴春福教授主持,刘建勋、孙晓波、段大跃和吕圭源教授作主题报告。中国药理学会理事长兼中药与天然药物药理专业委员会主任委员张永祥研究员主持综合讨论,国家卫生健康委员会科技教育司重大专项处顾金辉处长全程参加。与会专家围绕中药复方新药研发相关重大科学和技术问题进行了广泛、深入的讨论。本文整理了专家们的主要观点和建议,希望能为中药复方新药研发提供新思路和新技术,为提高我国中药复方新药的研发水平发挥积极的推动作用。

关键词：中药复方新药研发新思路新技术

在线全文

学校读者我要写书评

暂无评论

非小细胞肺癌少见/罕见靶点:共识与争鸣

循证医学 2023年第3期23卷 129-139页

作者：吴一龙陆舜程颖周清涂海燕周清华王绿化张力周建英黄诚陈明胡成平揣少坤汪笑男刘晓晴刘基巍周鹏辉陈维之严令华刘云鹏刘安文张绪超李慧陈蓉蓉林冬梅谢聪颖朱正飞梁会营宋勇董晓荣赵明芳乔贵宾崔久嵬李子明王志杰陈晓媛杨农林根田攀文范云宋启斌陈元段建春王佳蕾朱波汪步海赵军于起涛王立峰张海波胡洁马锐张同梅林劼褚倩任胜祥姚煜邬麟王慧娟吴芳钟文昭胡毅陈克能赵健张力杨帆王群岳东升周建娅申鹏张嘉涛闫小龙黄媚娟冯卫能李力中国抗癌协会肺癌专业委员会广东省临床试验协会/中国胸部肿瘤研究协作组不详广东省肺癌研究所南方医科大学附属广东省人民医院(广东省医学科学院)广州510080 上海交通大学附属胸科医院上海200030 吉林省肿瘤医院长春130021 四川大学华西医院成都610041 中国医学科学院肿瘤医院深圳医院广东深圳518116 中山大学肿瘤防治中心广州510060 浙江大学医学院附属第一医院杭州310031 福建省肿瘤医院福州350011 中南大学湘雅医院长沙410008 广州燃石医学检验所有限公司广州510300 南京世和基因生物技术股份有限公司南京210032 解放军总医院北京100071 大连医科大学附属第一医院辽宁大连116011 无锡臻和生物科技有限公司江苏无锡214105 上海桐树生物科技有限公司上海200444 中国医科大学附属第一医院沈阳110001 南昌大学附属第二医院南昌330006 北京吉因加科技有限公司北京102206 北京大学肿瘤医院北京100142 温州医科大学附属第二医院浙江温州325027 复旦大学附属肿瘤医院上海200032 东部战区总医院南京210002 华中科技大学同济医学院附属协和医院武汉430022 吉林大学白求恩第一医院长春130021 中国医学科学院肿瘤医院北京100021 清华大学医学院北京100084 湖南省肿瘤医院长沙410013 中国科学院大学附属肿瘤医院/浙江省肿瘤医院杭州310022 武汉大学人民医院肿瘤中心武汉430060 华中科技大学同济医学院附属同济医院武汉430030 陆军军医大学第二附属医院-新桥医院重庆400037 南京大学医学院附属苏北人民医院江苏扬州225001 广西医科大学附属肿瘤医院南宁530012 南京大学医学院附属鼓楼医院南京210008 广东省中医院广州510120 复旦大学附属中山医院上海200032 辽宁省肿瘤医院沈阳110042 首都医科大学附属北京胸科医院北京101149 昆明医科大学第二附属医院昆明650101 同济大学附属上海市肺科医院上海200433 西安交通大学第一附属医院西安710061 郑州大学附属肿瘤医院/河南省肿瘤医院郑州450003 中南大学湘雅二医院长沙410011 广州医科大学附属肿瘤医院广州510095 北京协和医院北京100032 北京大学人民医院北京100044 天津医科大学肿瘤医院天津300060 南方医科大学南方医院广州510515 空军军医大学唐都医院西安710038 佛山市第一人民医院广东佛山528000 陆军军医大学大坪医院重庆400042

由中国抗癌协会肺癌专业委员会和广东省临床试验协会/中国胸部肿瘤研究协作组主办的“第20届中国肺癌高峰论坛”于2023年3月4日在广州顺利召开。此次论坛以非小细胞肺癌(non-small cell lung cancer,NSCLC)少见/罕见靶点为主题,从少见/... 详细信息

由中国抗癌协会肺癌专业委员会和广东省临床试验协会/中国胸部肿瘤研究协作组主办的“第20届中国肺癌高峰论坛”于2023年3月4日在广州顺利召开。此次论坛以非小细胞肺癌(non-small cell lung cancer,NSCLC)少见/罕见靶点为主题,从少见/罕见靶点的精准检测、新型临床研究与围术期治疗等角度开展相关学术探讨,并最终达成了专家共识。

关键词：非小细胞肺癌少见/罕见靶点共识争鸣

在线全文

学校读者我要写书评

暂无评论

复方氨基酸注射液临床应用专家共识

肿瘤代谢与营养电子杂志 2019年第2期6卷 183-189页

作者：高纯李梦韦军民李玉珍田伟军姜海平沈威许爱国余震陈东生陈莲珍管文贤江华李大魁梅丹于吉人赵春临范伟胡松康焰康维明吕传柱刘东刘辉吕永宁孟翔凌宋金春孙明伟汤庆娅王烈王景杰吴东方许媛徐华颜伟慧闫雪莲曾俊张片红龚建平郭增清胡俊波孟庆华李增宁钱素云秦宝丽沈荣田字彬许红霞姚颖于乐成石汉平华中科技大学同济医学院附属同济医院北京医院 /国家老年医学中心北京大学人民医院天津医科大学总医院暨南大学附属第一医院南昌大学第二附属医院郑州大学第一附属医院同济大学附属第十人民医院华中科技大学同济医学院附属协和医院国家癌症中心 /国家肿瘤临床医学中心 /中国医学科学院北京协和医学院肿瘤医院南京大学医学院附属鼓楼医院四川省医学科学院·四川省人民医院北京协和医院浙江大学医学院附属第一医院贵州省人民医院武汉市第一医院四川大学华西医院海南医学院中国人民解放军中部战区总医院安徽医科大学第一附属医院武汉大学人民医院上海交通大学医学院附属新华医院中国人民解放军联勤部第 900 医院空军军医大学唐都医院武汉大学中南医院北京清华长庚医院武汉儿童医院浙江大学医学院附属第二医院福建省肿瘤医院 /福建医科大学附属肿瘤医院首都医科大学附属北京佑安医院河北医科大学第一医院首都医科大学附属北京儿童医院辽宁省肿瘤医院浙江大学公共卫生学院青岛大学附属医院陆军军医大学大坪医院东部战区总医院南京中医药大学附属八一医院首都医科大学附属北京世纪坛医院中华医学会肠外肠内营养学分会中国抗癌协会肿瘤营养专业委员会

复方氨基酸注射液是肠外营养中氮的来源,广泛应用于不能经胃肠道给予或经胃肠道给予不能满足其营养需求的患者,在营养治疗中起重要作用。但目前对于复方氨基酸注射液临床应用的指征、剂型、剂量、时机,国内并无系统的指南或共识。为了... 详细信息

复方氨基酸注射液是肠外营养中氮的来源,广泛应用于不能经胃肠道给予或经胃肠道给予不能满足其营养需求的患者,在营养治疗中起重要作用。但目前对于复方氨基酸注射液临床应用的指征、剂型、剂量、时机,国内并无系统的指南或共识。为了进一步规范复方氨基酸注射液的临床应用,中华医学会肠外肠内营养学分会(Chinese Society for Parenteral and Enteral Nutrition,CSPEN)及中国抗癌协会肿瘤营养专业委员会(Chinese Society of Nutritional Oncology,CSNO)组织全国专家,在系统性文献检索的基础上,参考美国肠外肠内营养学会(American Society for Parenteral and Enteral Nutrition,ASPEN)、欧洲临床营养和代谢学会(European Society for Clinical Nutrition and Metabolism,ESPEN)、CSPEN及CSNO指南,结合我国临床实践,经多次交流讨论,达成此共识。包括10条推荐意见,涉及不同患者的蛋白质需要量及氨基酸剂型选择。

关键词：复方氨基酸注射液肠外营养蛋白质营养治疗专家共识